Aatonomy sees autonomous vehicles as inefficient and unsafe. That's why the Houston startup is doing something differently. Sean Pavone/Getty Images

When there isn't a global pandemic, nearly 7 million people drive around Houston, and an estimated 77,000 people commute for more than an hour and a half to work. Drivers spend $1,376 and waste 31 gallons of fuel a year — to sit in traffic for what adds up to 75 hours each year.

When Wilson Pulling moved to the city two summers ago, he set out to fix all that traffic-sitting using autonomously driven cars, but not the high-priced ones that Uber and Tesla have designed. These are your regular, three- or four-year-old Honda Civics and Kia Sorentos — the cars you already own.

In 2016, Pulling founded had Aatonomy with his partner, Yang Hu, based on their thesis work from Cornell's Computer Science program. Moving the company south after two years operating out of San Francisco, they aimed not to build the self-driving car of the future, but to make the cars that Houstonians are wading through congested freeways in today drive themselves.

"Everyone doesn't get to buy a Tesla. They're driving their Corollas," Pulling says. "The way autonomy is going right now, that person is never going to benefit. We are the only way."

The company's technology attaches a wireless receiver to the car, which has to be from at least 2016 to work with them. Then, Aatonomy places sensors all along the roads and streetlights. The sensors and receiver communicate with each other, and enable autonomous driving.

Imagine, Pulling says, a 30-mile of I-45 with Aatonomy's sensors. You'd roar up the freeway, handling the controls. Then, the car's computer, under guidance from Aatonomy's network of sensors, would take over. You'd sit back, the car will navigate the traffic along with the other cars — and if all the cars are autonomous, Pulling says, the algorithm could slash congestion. When your car exits the freeway, you'd take back control.

That stretch of freeway would cost $26 million for 200,000 commuters across Houston, Pulling says, but other self-driving cars cost around $250,000 per vehicle — summing up to $50 billion for those same commuters. And Pulling says the Aatonomy system is a safer bet than the way Uber's autonomous driving. Uber's car once killed a pedestrian because, somehow, the company didn't program it to avoid people jaywalking. But because Aatonomy will manage sensors all over the street, the company will be able to monitor potential accidents more quickly than an Uber car would.

"This is a really radically different approach to a technology that, frankly, a lot of people have lost a lot of faith in," Pulling says.

Aatonomy's approach requires a smart city commitment — but the city of Houston is already buying in. First, Aatonomy, a member of the Ion Smart and Resilient Cities accelerator's inaugural cohort, got a short-term project with Aatonomy and Verizon to mount intersection cameras for studying how to prevent collisions with pedestrians on the Northside.

Additionally, the city has also greenlit a two-year pilot with Aatonomy to automate a bus route in downtown Houston. The aim, Pulling says, is making a "proof-of-concept" before rolling out sensors across I-45 — but it's also to use Houston as proof that autonomous driving can be achieved, but from a different angle than Uber.

"Self driving cars don't work. That's our thesis," Pulling says. "That's why we're building self-driving cities."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.